Short Interest in Benitec Biopharma Inc. (NASDAQ:BNTC) Grows By 6.9%

Benitec Biopharma Inc. (NASDAQ:BNTC - Get Free Report) saw a significant growth in short interest in November. As of November 30th, there was short interest totalling 35,400 shares, a growth of 6.9% from the November 15th total of 33,100 shares. Based on an average trading volume of 39,100 shares, the short-interest ratio is presently 0.9 days.

Benitec Biopharma Stock Down 4.7 %

BNTC stock traded down $0.58 during midday trading on Friday, hitting $11.77. The stock had a trading volume of 52,248 shares, compared to its average volume of 46,012. The stock has a 50-day simple moving average of $10.55 and a 200 day simple moving average of $9.29. Benitec Biopharma has a 52 week low of $2.69 and a 52 week high of $13.22.

Insider Transactions at Benitec Biopharma

In other news, Director Suvretta Capital Management, L acquired 42,000 shares of the firm's stock in a transaction that occurred on Tuesday, December 3rd. The stock was acquired at an average cost of $9.60 per share, with a total value of $403,200.00. Following the acquisition, the director now owns 7,957,365 shares in the company, valued at approximately $76,390,704. This represents a 0.53 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 1.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Benitec Biopharma

A number of hedge funds and other institutional investors have recently made changes to their positions in BNTC. GAMMA Investing LLC increased its stake in Benitec Biopharma by 20.3% in the third quarter. GAMMA Investing LLC now owns 6,540 shares of the biotechnology company's stock valued at $60,000 after acquiring an additional 1,102 shares during the period. Acuta Capital Partners LLC acquired a new stake in Benitec Biopharma during the third quarter valued at approximately $274,000. Simplify Asset Management Inc. bought a new stake in shares of Benitec Biopharma in the 2nd quarter valued at approximately $358,000. Geode Capital Management LLC raised its holdings in shares of Benitec Biopharma by 31.3% in the 3rd quarter. Geode Capital Management LLC now owns 83,987 shares of the biotechnology company's stock worth $772,000 after buying an additional 20,012 shares in the last quarter. Finally, Nantahala Capital Management LLC acquired a new position in shares of Benitec Biopharma in the 2nd quarter worth approximately $5,881,000. 52.19% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on BNTC shares. JMP Securities lifted their price objective on Benitec Biopharma from $16.00 to $18.00 and gave the stock a "market outperform" rating in a research note on Monday, October 14th. Piper Sandler reissued an "overweight" rating on shares of Benitec Biopharma in a research report on Friday, October 18th. Oppenheimer assumed coverage on shares of Benitec Biopharma in a research report on Wednesday, October 16th. They set an "outperform" rating and a $35.00 target price on the stock. Robert W. Baird started coverage on shares of Benitec Biopharma in a report on Friday. They issued an "outperform" rating and a $30.00 price target for the company. Finally, Guggenheim restated a "buy" rating and set a $17.00 price objective on shares of Benitec Biopharma in a report on Tuesday, December 3rd. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, Benitec Biopharma currently has a consensus rating of "Buy" and a consensus target price of $23.83.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.